多奈哌齐对阿尔茨海默病患者血清学指标的影响
发布时间：2018-08-29 07:35
【摘要】：目的探讨多奈哌齐对阿尔茨海默病(AD)患者临床疗效。方法 AD患者按照简易智能精神状态量表(MMSE),分为轻度、中度和重度组各40例。所有患者治疗前2 w停用其他治疗药物,前4 w给予多奈哌齐5 mg/d口服,4~8 w给予10 mg/d口服,疗程24 w,同时选取36例健康老年体检者进行对照。对各组患者的治疗前后MMSE评分、血清同型半胱氨酸(HCY)、载脂蛋白E(ApoE)和C反应蛋白(CRP)进行测定。结果多奈哌齐治疗后轻度、中度和重度AD患者MMSE评分与治疗前相比有明显的改善(P0.01,P0.01,P=0.012)。临床疗效比较发现三组患者治疗结果有一定的差异(χ2=10.43,P=0.005),多奈哌齐对轻度和中度AD患者缓解程度明显强于重度AD患者(χ2=9.038,P=0.003;χ2=4.267,P=0.039)。各组AD患者的CRP和HCY较健康对照组有显著升高(P0.01,P0.01和P0.01),而且随着疾病程度的加重,CRP与HCY水平也逐渐显著提升(P0.05);而各组AD患者的ApoE较健康对照组有显著下降(P0.01,P0.01和P0.01),而且随着疾病程度的加重,ApoE水平也逐渐下降,但无显著差异(P0.05)。轻度、中度和重度AD患者治疗有效患者的CRP和HCY水平较无效患者显著下降(P0.05),而ApoE水平则无明显变化(P0.05)。结论多奈哌齐对不同程度AD患者,尤其是轻中度AD患者有显著的临床和血清学疗效,且无明显的副作用,安全性高。
[Abstract]:Objective to investigate the clinical effect of Donepezil on (AD) patients with Alzheimer's disease. Methods AD patients were divided into mild, moderate and severe groups according to simple Mental State scale (MMSE),). All the patients stopped taking other drugs 2 weeks before treatment, and 4 weeks after treatment, the patients were treated with Donepezil for 5 mg/d and 4 weeks for 10 mg/d. The course of treatment was 24 weeks. At the same time, 36 healthy elderly people were selected as control group. MMSE scores, serum homocysteine (HCY), apolipoprotein E (ApoE) and C-reactive protein (CRP) were measured before and after treatment. Results the MMSE scores of mild, moderate and severe AD patients were significantly improved after Donepezil treatment (P0.01, P0.01, P0.012). There were some differences in the treatment results among the three groups (蠂 ~ 2 / 10. 43 / P ~ (0.005). The remission degree of Donepezil in mild and moderate AD patients was significantly higher than that in severe AD patients (蠂 ~ (2) 9.038 / P ~ (0.003); 蠂 ~ (2) 4.267) P ~ (0.039). The levels of CRP and HCY in AD patients in each group were significantly higher than those in healthy control group (P0.01 and P0.01), and the levels of CRP and HCY increased gradually with the severity of disease (P0.05), while the ApoE levels in AD patients in each group were significantly lower than those in the healthy control group (P0.01 and P0.01), while those in AD patients in each group were significantly lower than those in the healthy control group (P0.01 and P0.01). The ApoE level decreased gradually with the severity of the disease. But there was no significant difference (P0.05). The levels of CRP and HCY in mild, moderate and severe AD patients were significantly lower than those in ineffective patients (P0.05), while ApoE levels did not change significantly (P0.05). Conclusion Donepezil has significant clinical and serological efficacy in patients with different levels of AD, especially in mild and moderate AD patients, with no obvious side effects and high safety.
【作者单位】： 辽宁省人民医院神经内二科;
【分类号】：R749.16
[Abstract]:Objective to investigate the clinical effect of Donepezil on (AD) patients with Alzheimer's disease. Methods AD patients were divided into mild, moderate and severe groups according to simple Mental State scale (MMSE),). All the patients stopped taking other drugs 2 weeks before treatment, and 4 weeks after treatment, the patients were treated with Donepezil for 5 mg/d and 4 weeks for 10 mg/d. The course of treatment was 24 weeks. At the same time, 36 healthy elderly people were selected as control group. MMSE scores, serum homocysteine (HCY), apolipoprotein E (ApoE) and C-reactive protein (CRP) were measured before and after treatment. Results the MMSE scores of mild, moderate and severe AD patients were significantly improved after Donepezil treatment (P0.01, P0.01, P0.012). There were some differences in the treatment results among the three groups (蠂 ~ 2 / 10. 43 / P ~ (0.005). The remission degree of Donepezil in mild and moderate AD patients was significantly higher than that in severe AD patients (蠂 ~ (2) 9.038 / P ~ (0.003); 蠂 ~ (2) 4.267) P ~ (0.039). The levels of CRP and HCY in AD patients in each group were significantly higher than those in healthy control group (P0.01 and P0.01), and the levels of CRP and HCY increased gradually with the severity of disease (P0.05), while the ApoE levels in AD patients in each group were significantly lower than those in the healthy control group (P0.01 and P0.01), while those in AD patients in each group were significantly lower than those in the healthy control group (P0.01 and P0.01). The ApoE level decreased gradually with the severity of the disease. But there was no significant difference (P0.05). The levels of CRP and HCY in mild, moderate and severe AD patients were significantly lower than those in ineffective patients (P0.05), while ApoE levels did not change significantly (P0.05). Conclusion Donepezil has significant clinical and serological efficacy in patients with different levels of AD, especially in mild and moderate AD patients, with no obvious side effects and high safety.
【作者单位】： 辽宁省人民医院神经内二科;
【分类号】：R749.16
【参考文献】
相关期刊论文 前4条
1 邵t，
本文编号：2210629
本文链接：https://www.wllwen.com/yixuelunwen/jsb/2210629.html
最近更新
教材专著
